• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].

作者信息

Bai J F, Feng R, Han H X, Wang T, Li J T, Zhang C L, Liu H

机构信息

Department of Hematology, Beijing Hospital, Beijing 100730, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1047-1049. doi: 10.3760/cma.j.issn.0253-2727.2019.12.016.

DOI:10.3760/cma.j.issn.0253-2727.2019.12.016
PMID:32023740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342678/
Abstract
摘要

相似文献

1
[Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].来那度胺、利妥昔单抗和地塞米松治疗复发/难治性或老年新诊断的原发性中枢神经系统淋巴瘤患者：5例报告及文献复习
Zhonghua Xue Ye Xue Za Zhi. 2019 Dec 14;40(12):1047-1049. doi: 10.3760/cma.j.issn.0253-2727.2019.12.016.
2
Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.来那度胺、利妥昔单抗和甲氨蝶呤对新诊断的原发性中枢神经系统淋巴瘤有效。
Haematologica. 2024 Jun 1;109(6):2005-2009. doi: 10.3324/haematol.2023.284834.
3
Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study.奥布替尼联合利妥昔单抗和来那度胺治疗低KPS评分老年初诊原发性中枢神经系统淋巴瘤患者的有效性和安全性——一项单中心回顾性研究
Neurol Sci. 2024 Jun;45(6):2931-2934. doi: 10.1007/s10072-024-07348-4. Epub 2024 Feb 7.
4
Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.甲氨蝶呤-阿糖胞苷-地塞米松联合化疗联合或不联合利妥昔单抗治疗原发性中枢神经系统淋巴瘤患者。
Oncotarget. 2017 Jul 25;8(30):49156-49164. doi: 10.18632/oncotarget.17101.
5
Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.来那度胺用于接受全脑放疗后不适合强化全身治疗的原发性中枢神经系统淋巴瘤患者。
Br J Haematol. 2023 Apr;201(1):150-153. doi: 10.1111/bjh.18659. Epub 2023 Jan 22.
6
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.来那度胺联合静脉利妥昔单抗（REVRI）治疗复发/难治性原发性中枢神经系统淋巴瘤或原发性眼内淋巴瘤：法国眼脑淋巴瘤（LOC）网络和淋巴瘤研究协会（LYSA）的多中心前瞻性“概念验证”二期研究†。
Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.
7
Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.利妥昔单抗与替莫唑胺联合免疫化疗用于中枢神经系统淋巴瘤
Cancer. 2004 Jul 1;101(1):139-45. doi: 10.1002/cncr.20339.
8
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.利妥昔单抗、甲氨蝶呤、丙卡巴肼、长春新碱及强化阿糖胞苷巩固治疗老年原发性中枢神经系统淋巴瘤（PCNSL）：一项LOC网络研究
J Neurooncol. 2017 Jun;133(2):315-320. doi: 10.1007/s11060-017-2435-7. Epub 2017 Apr 21.
9
[Therapeutic management of central nervous system lymphomas in a single hematological institute].[单一血液学机构中中枢神经系统淋巴瘤的治疗管理]
Orv Hetil. 2009 Oct 18;150(42):1937-44. doi: 10.1556/OH.2009.28703.
10
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.基于普拉曲沙和阿糖胞苷的挽救治疗用于原发性中枢神经系统淋巴瘤。
J Neurooncol. 2011 Nov;105(2):409-14. doi: 10.1007/s11060-011-0608-3. Epub 2011 Jun 9.

本文引用的文献

1
Primary CNS Lymphoma.原发性中枢神经系统淋巴瘤
J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22.
2
Demyelination preceding a diagnosis of central nervous system lymphoma.中枢神经系统淋巴瘤诊断前的脱髓鞘病变。
J Clin Neurosci. 2016 Feb;24:146-8. doi: 10.1016/j.jocn.2015.07.013. Epub 2015 Oct 9.
3
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.免疫健全患者原发性中枢神经系统淋巴瘤的诊断与治疗：来自欧洲神经肿瘤学会的指南。
Lancet Oncol. 2015 Jul;16(7):e322-32. doi: 10.1016/S1470-2045(15)00076-5.
4
Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.来那度胺联合利妥昔单抗克服惰性 B 细胞和套细胞淋巴瘤患者对利妥昔单抗的耐药性。
Clin Cancer Res. 2015 Apr 15;21(8):1835-42. doi: 10.1158/1078-0432.CCR-14-2221. Epub 2015 Jan 28.
5
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.来那度胺单药治疗作为复发性原发性中枢神经系统淋巴瘤的挽救治疗方法。
Neurology. 2015 Jan 20;84(3):325-6. doi: 10.1212/WNL.0000000000001158. Epub 2014 Dec 19.
6
Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.原发性中枢神经系统淋巴瘤发病和生存的年龄、性别和种族差异。
Br J Cancer. 2011 Oct 25;105(9):1414-8. doi: 10.1038/bjc.2011.357. Epub 2011 Sep 13.
7
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.原发性中枢神经系统淋巴瘤的生物学、诊断、鉴别诊断和治疗的现代概念。
Leukemia. 2011 Dec;25(12):1797-807. doi: 10.1038/leu.2011.169. Epub 2011 Aug 5.
8
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.抗癌药物来那度胺通过在常氧和低氧条件下对内皮细胞功能的多种抑制作用来抑制血管生成和转移。
Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4.
9
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.免疫调节药物来那度胺（Revlimid，通用名：lenalidomide）和CC - 4047通过激活自然杀伤细胞（NK细胞）诱导血液肿瘤细胞和实体瘤细胞凋亡。
Cancer Immunol Immunother. 2008 Dec;57(12):1849-59. doi: 10.1007/s00262-008-0512-7. Epub 2008 Apr 8.